By Aware and Prepare
As we have recently reported, Gardasil HPV Vaccine does not provide more benefit than risk and there the evidence based medicine is not there to back it. Information such as this in addition to the multitude of vaccine side effects, vaccine injury and vaccine deaths people have suffered, SANEVax has sent a letter to Secretary of Health, Kathleen Sabelius to consider rescinding the approval of Gardasil HPV Vaccine in light of the fact that it does not prove effective in post approval studies.
According to a recently published, industry-sponsored study conducted on 12,852 young women, HPV vaccination was found to reduce HPV-16 infections a mere 0.6% in vaccinated women versus unvaccinated women. At the same time, other high-risk (carcinogenic) HPV infections were diagnosed in vaccinated women 2.6% to 6.2% more frequently than in the unvaccinated women. The increased rate of infections caused by carcinogenic HPV types other than those targeted by Gardasil® in vaccinated women is 4 to 10 times higher than the reduction in HPV 16/18 infections.
These statistics are not exactly encouraging when it comes to demonstrating efficacy for Gardasil®. In fact, quite the opposite – these figures seem to indicate that women who receive Gardasil® may indeed increase their risk of developing cervical cancer from high-risk HPV types that are not targeted by the vaccine.